Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

333
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
333
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

256
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
256
Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

11.6K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
11.6K
Serum Studies: Renal Function Tests01:24

Serum Studies: Renal Function Tests

599
Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
599
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

1.2K
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
1.2K
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate01:25

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

100
The glomerular filtration rate (GFR) is a critical indicator of kidney health, reflecting how well the kidneys filter blood. Changes in GFR can signal potential kidney impairment, necessitating accurate measurement methods to monitor kidney function effectively.Various molecules can serve as markers for GFR measurement, with the ideal marker meeting several specific criteria. It must freely filter at the glomerulus, avoid reabsorption or secretion by the renal tubules, remain unmetabolized, not...
100

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heparin-binding protein and Endothelin-1 in critical COVID-19.

BMC anesthesiology·2026
Same author

Predictive validity of daily sequential organ failure assessment (SOFA)-2 score for 30-day mortality.

Critical care (London, England)·2026
Same author

Time course of energy expenditure in persistent critical illness: a prospective multicentre study.

Critical care (London, England)·2026
Same author

Long-Term Risk of Chronic Kidney Disease After Continuous Renal Replacement Therapy in Critically Ill Children: Single-Center PICU Cohort in Sweden, 2008-2021.

Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·2026
Same author

Plasma sodium as a predictor of perforation in acute appendicitis: A prospective multi-centre study.

Journal of pediatric surgery·2026
Same author

Muscle catabolism: mechanisms and functional consequences in critically ill patients.

Intensive care medicine·2026

Related Experiment Video

Updated: Mar 24, 2026

Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer
08:37

Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer

Published on: November 15, 2024

846

Plasma Glutamine Concentrations in Liver Failure.

Gunnel Helling1, Staffan Wahlin2, Marie Smedberg1

  • 1Department of Anesthesia & Intensive Care, Karolinska University Hospital Huddinge and Karolinska Institutet, Stockholm, Sweden.

Plos One
|March 4, 2016
PubMed
Summary

High plasma glutamine levels are common in liver failure patients, regardless of illness severity. Further research is needed to determine if elevated glutamine is a biomarker or contributes to symptoms in liver failure.

More Related Videos

Glutamine Flux Imaging Using Genetically Encoded Sensors
10:23

Glutamine Flux Imaging Using Genetically Encoded Sensors

Published on: July 31, 2014

10.1K
Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)
07:15

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)

Published on: July 3, 2025

813

Related Experiment Videos

Last Updated: Mar 24, 2026

Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer
08:37

Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer

Published on: November 15, 2024

846
Glutamine Flux Imaging Using Genetically Encoded Sensors
10:23

Glutamine Flux Imaging Using Genetically Encoded Sensors

Published on: July 31, 2014

10.1K
Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)
07:15

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)

Published on: July 3, 2025

813

Area of Science:

  • Biochemistry
  • Hepatology
  • Critical Care Medicine

Background:

  • Elevated plasma glutamine is linked to poor outcomes in intensive care units.
  • Very high glutamine levels are observed in acute and chronic liver failure.
  • The relationship between liver failure types and glutamine concentrations requires systematic investigation.

Purpose of the Study:

  • To systematically explore the association between different types of liver failure and plasma glutamine concentrations.
  • To investigate the correlation between liver failure severity and plasma glutamine levels.

Main Methods:

  • Studied four patient groups: chronic liver failure (n=40), acute on chronic liver failure (n=20), acute fulminant liver failure (n=20), and post-hepatectomy liver failure (n=20).
  • Assessed liver function using Child-Pugh and Model for End-stage Liver Disease (MELD) scores.
  • Longitudinal follow-up during hospitalization and outcomes recorded up to 48 months.

Main Results:

  • All patient groups exhibited individuals with very high plasma glutamine concentrations.
  • A significant, though not strong, correlation was found between liver failure severity and plasma glutamine concentration in the total patient cohort (n=100).

Conclusions:

  • Liver failure, irrespective of its severity or disease course, can be associated with elevated plasma glutamine levels.
  • Further research is necessary to clarify whether high glutamine concentrations serve as a biomarker or a contributing factor to liver failure symptoms.